[Abstract Title]. - Society for Neuroscience

The mice were acclimated to the running wheel cages for 3-4 days before the beginning of the
study, and baseline levels of activity for each mouse was determined by allowing 6 days of
unrestricted running. Pilot studies showed that running wheel activity begins 2-3 hours before the
beginning of the dark cycle, peaks around the time of lights-out, and gradually declines steadily
over the next 12 hours. Subjects were stratified into treatment groups based on activity levels and
were then dosed i.pl. with either CFA, carrageenan or vehicle.
CFA administration reduced running wheel activity to 40% of baseline levels for the first day
after injection, with a gradual recovery over the next four days, whereas i.pl. saline did not have
a significant effect on running. This reduction was dose-dependently reversed by oral
administration the NSAID indomethacin (0.3, 3, and 30 mg/kg). The mixed opioid receptor
ligand buprenorphine (1 mg/kg, p.o.), reversed CFA-induced reductions in wheel running to 90%
of control. The antidopaminergic drug haloperidol (1 mg/kg, p.o.) was also fully efficacious in
this model, in contrast to purported non-antinociceptive effects in rodents. These initial studies
suggest that pain-suppressed wheel running might be an alternative behavioral endpoint to the
typical evoked pain endpoints.
Disclosures: D.J. Stone , Johnson & Johnson Pharmaceutical Research and Development, A.
Employment (full or part-time); R.W. Colburn, Johnson & Johnson Pharma R&D, A.
Employment (full or part-time); C.M. Flores, Johnson & Johnson Pharma R&D, A.
Employment (full or part-time); M.R. Brandt, Johnson & Johnson Pharma R&D, A.
Employment (full or part-time).
Poster
267. Pain: Pain Models II
Time: Sunday, November 16, 2008, 1:00 pm - 5:00 pm
Program#/Poster#: 267.12/FF18
Topic: D.08.j. Pain models
Support: WSU, Department of Anesthesiology Research Fund
R01 DA-16736 (MPG).
Joe Young Research Fund in Psychiatry
Title: Metabolic profile of the rat brain using streptozotocin as a model for neuropathic pain:
studies with proton magnetic resonance spectroscopy (MRS)